Randomized, double-blind, placebo-controlled, dose-escalating phase I, healthy subjects study of intravenous OPN-305, a humanized anti-TLR2 antibody.

Reilly M, Miller RM, Thomson MH, Patris V, Ryle P, McLoughlin L, Mutch P, Gilboy P, Miller C, Broekema M, Keogh B, McCormack W, van de Wetering de Rooij J

Open source

DOI: 10.1038/clpt.2013.150
Published: 2013 Nov
Container: Clinical pharmacology and therapeutics
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1038/clpt.2013.150,
  title = {Randomized, double-blind, placebo-controlled, dose-escalating phase I, healthy subjects study of intravenous OPN-305, a humanized anti-TLR2 antibody.},
  author = {Reilly M and Miller RM and Thomson MH and Patris V and Ryle P and McLoughlin L and Mutch P and Gilboy P and Miller C and Broekema M and Keogh B and McCormack W and van de Wetering de Rooij J},
  year = {2013},
  journal = {Clinical pharmacology and therapeutics},
  doi = {10.1038/clpt.2013.150},
  url = {https://doi.org/10.1038/clpt.2013.150}
}

RIS

TY  - JOUR
TI  - Randomized, double-blind, placebo-controlled, dose-escalating phase I, healthy subjects study of intravenous OPN-305, a humanized anti-TLR2 antibody.
AU  - Reilly M
AU  - Miller RM
AU  - Thomson MH
AU  - Patris V
AU  - Ryle P
AU  - McLoughlin L
AU  - Mutch P
AU  - Gilboy P
AU  - Miller C
AU  - Broekema M
AU  - Keogh B
AU  - McCormack W
AU  - van de Wetering de Rooij J
PY  - 2013
JO  - Clinical pharmacology and therapeutics
DO  - 10.1038/clpt.2013.150
UR  - https://doi.org/10.1038/clpt.2013.150
ER  -

APA

M, R., RM, M., MH, T., V, P., P, R., L, M., P, M., P, G., C, M., M, B., B, K., W, M., & J, V. D. W. D. R. (2013). Randomized, double-blind, placebo-controlled, dose-escalating phase I, healthy subjects study of intravenous OPN-305, a humanized anti-TLR2 antibody.. Clinical pharmacology and therapeutics. https://doi.org/10.1038/clpt.2013.150

Source records

pubmed · retrieved 2026-09-26T12:22:50.835Z